Medicine combination for treating pericardial effusion and preventing complications

A technology for pericardial effusion and complications, which is applied in the field of pharmaceutical compositions for treating pericardial effusion and preventing complications, can solve the problems of unavoidable recurrence of complications, inaccurate disease control, increased risks, etc., so as to enhance human immunity The effect of improving anti-tumor and soothing emotions

Inactive Publication Date: 2016-11-30
王巧玲
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is no unified conclusion on the treatment plan for this disease. Most patients are given treatment plans based on the doctor's personal experience. It is inevitable that there will be problems such as inaccurate control of the disease. Drug treatment generally uses ordinary anti-inflammatory drugs, and surgery Therapy not only increases the risk, but also cannot avoid the possibility of recurrence and various postoperative complications, and lacks a way to start with the cause of the disease to achieve the most effective treatment goal. The disease is mostly caused by infection or tumor, Complications caused by rheumatism, cardiovascular injury and other diseases, so under the premise of anti-inflammatory treatment, combined with anti-tumor, anti-cancer, and drug coordination treatment to enhance the body's immune ability, in order to achieve good curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine combination for treating pericardial effusion and preventing complications
  • Medicine combination for treating pericardial effusion and preventing complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The pharmaceutical composition for treating pericardial effusion and preventing complications is mainly composed of the following ingredients in parts by weight: 0.4 parts of 4-pyridinecarbohydrazide, 0.1 parts of ofloxacin, 4.2 parts of apigenin, and 3.7 parts of hollynin 3.4 parts of ursolic acid, 3.1 parts of scopolamine, 2.6 parts of ergosterol, 2.3 parts of horse chestnut bark, 1.9 parts of oleanolic acid, 1.6 parts of oligosaccharides, 1.3 parts of oridonin, vitamin B2 0.005 parts, vitamin C 0.003 parts, low-substituted hydroxypropyl cellulose 10 parts.

[0020] Wherein, the said hollyside is Ilexin J, which is obtained by degrading the sugar chain of Ilexin O by alkali degradation method. Ilexin J has good antithrombotic pharmacological activity, and is of great importance to the research on the treatment of cardiovascular diseases. Significance, described alkali is the KOH solution that mass concentration is 7%; Described oligosaccharide comprises trehalose and ...

Embodiment 2

[0026] The pharmaceutical composition for treating pericardial effusion and preventing complications is mainly composed of the following ingredients in parts by weight: 0.95 parts of 4-pyridinecarbohydrazide, 0.4 parts of ofloxacin, 6.4 parts of apigenin, and 5.9 parts of hollynin 5.5 parts of ursolic acid, 5.15 parts of scopoletin, 4.6 parts of ergosterol, 4.2 parts of horse chestnut bark, 3.8 parts of oleanolic acid, 3.4 parts of oligosaccharides, 3 parts of oridonin, vitamin B2 0.011 parts, vitamin C 0.007 parts, low-substituted hydroxypropyl cellulose 17.5 parts.

[0027] Wherein, the said hollyside is Ilexin J, which is obtained by degrading the sugar chain of Ilexin O by alkali degradation method. Ilexin J has good antithrombotic pharmacological activity, and is of great importance to the research on the treatment of cardiovascular diseases. Significance, described alkali is the KOH solution that mass concentration is 7%; Described oligosaccharide comprises trehalose and...

Embodiment 3

[0033] The pharmaceutical composition for treating pericardial effusion and preventing complications is mainly composed of the following ingredients in parts by weight: 1.5 parts of 4-pyridine carbohydrazide, 0.7 parts of ofloxacin, 8.6 parts of apigenin, and 8.1 parts of hollynin 7.6 parts of ursolic acid, 7.2 parts of scopolamine, 6.6 parts of ergosterol, 6.1 parts of horse chestnut bark, 5.7 parts of oleanolic acid, 5.2 parts of oligosaccharides, 4.7 parts of oridonin, vitamin B2 0.017 parts, vitamin C 0.011 parts, low-substituted hydroxypropyl cellulose 25 parts.

[0034] Wherein, the said hollyside is Ilexin J, which is obtained by degrading the sugar chain of Ilexin O by alkali degradation method. Ilexin J has good antithrombotic pharmacological activity, and is of great importance to the research on the treatment of cardiovascular diseases. Significance, described alkali is the KOH solution that mass concentration is 7%; Described oligosaccharide comprises trehalose and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine combination for treating pericardial effusion and preventing complications. The medicine combination for treating the pericardial effusion and preventing the complications comprises 4-isoniazid, ofloxacin, apigenin, ilexisaponin, ursolic acid, scopoletin, ergosterin, aesculetin, oleanolic acid, mycose, melitose, oridonin, vitamin B2, vitamin C, fillers, adhesives, disintegrating agents and lubricants. The medicine combination is used for treating the pericardial effusion, inflammation is controlled, metabolism is regulated by the aid of components for stopping pain, regulating qi, dispersing blood stasis, dredging collaterals and resisting viruses and tumors, symptoms of the pericardial effusion can be controlled, and diseases causing the pericardial effusion and the complications caused by the pericardial effusion can be relieved.

Description

technical field [0001] The invention relates to the technical field of cardiovascular medical medicine, in particular to a pharmaceutical composition for treating pericardial effusion and preventing complications. Background technique [0002] Due to its complex and variable pathogenesis, cardiovascular disease has become a common disease that seriously threatens human health. With the continuous development of modern medical technology, more diseases that were previously difficult to detect are gradually showing a significant upward trend in people's lives. The imperceptible concealment often brings more pain to patients. Pericardial effusion is a relatively common clinical manifestation and one of the important signs of pericardial disease. Pericardial effusion can be seen in exudative pericarditis and other non-inflammatory pericardial lesions. It can usually be confirmed by physical examination and X-ray examination. Especially after echocardiography became a routine ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/375A61K31/4409A61K31/525A61K31/5383A61K31/56A61K31/575A61K31/702A61K31/7024A61K9/20A61P29/00A61P31/12A61P35/00A61P3/00A61P39/00A61P31/00A61P37/04A61P31/06A61P9/00
CPCA61K9/2054A61K31/352A61K31/37A61K31/375A61K31/4409A61K31/525A61K31/5383A61K31/56A61K31/575A61K31/702A61K31/7024A61K2300/00
Inventor 王巧玲
Owner 王巧玲
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap